146 related articles for article (PubMed ID: 36209080)
1. Treatment of benign bone lesions with an injectable biphasic bone substitute.
Döring K; Rentenberger C; Kolb A; Patsch J; Puchner S; Windhager R; Chiari C
BMC Musculoskelet Disord; 2022 Oct; 23(1):901. PubMed ID: 36209080
[TBL] [Abstract][Full Text] [Related]
2. Early Clinical and Radiological Experience with a Ceramic Bone Graft Substitute in the Treatment of Benign and Borderline Bone Lesions.
Horstmann PF; Hettwer WH; Kaltoft NS; Petersen MM
Sci Rep; 2018 Oct; 8(1):15384. PubMed ID: 30337629
[TBL] [Abstract][Full Text] [Related]
3. Early postoperative compilations of bone filling in curettage defects.
Chen CJ; Brien EW
J Orthop Surg Res; 2019 Aug; 14(1):261. PubMed ID: 31419993
[TBL] [Abstract][Full Text] [Related]
4. Treatment alternatives and clinical outcomes of bone filling after benign tumour curettage. A systematic review.
Gava NF; Engel EE
Orthop Traumatol Surg Res; 2022 Jun; 108(4):102966. PubMed ID: 34033919
[TBL] [Abstract][Full Text] [Related]
5. Biphasic bone substitute and fibrin sealant for treatment of benign bone tumours and tumour-like lesions.
Reppenhagen S; Reichert JC; Rackwitz L; Rudert M; Raab P; Daculsi G; Nöth U
Int Orthop; 2012 Jan; 36(1):139-48. PubMed ID: 21626113
[TBL] [Abstract][Full Text] [Related]
6. Function after injection of benign bone lesions with a bioceramic.
Fillingham YA; Lenart BA; Gitelis S
Clin Orthop Relat Res; 2012 Jul; 470(7):2014-20. PubMed ID: 22290129
[TBL] [Abstract][Full Text] [Related]
7. Injectable Synthetic Beta-Tricalcium Phosphate/Calcium Sulfate (GeneX) for the Management of Contained Defects Following Curettage of Benign Bone Tumours.
Razii N; Docherty LM; Halai M; Mahendra A; Gupta S
Curr Oncol; 2023 Mar; 30(4):3697-3707. PubMed ID: 37185394
[TBL] [Abstract][Full Text] [Related]
8. Does bone marrow affect the radiological outcome when added to biphasic ceramic graft in treatment of benign bone lesions?
El-Adl G; Ali AM
Eur J Orthop Surg Traumatol; 2013 Jan; 23(1):13-20. PubMed ID: 23412403
[TBL] [Abstract][Full Text] [Related]
9. Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX®.
Friesenbichler J; Maurer-Ertl W; Sadoghi P; Pirker-Fruehauf U; Bodo K; Leithner A
Clin Orthop Relat Res; 2014 Mar; 472(3):976-82. PubMed ID: 24078171
[TBL] [Abstract][Full Text] [Related]
10. "Three-in-One minimally invasive approach to surgical treatment of pediatric pathological fractures with wide bone loss through bone cysts: ESIN, curettage and packing with injectable HA bone substitute. A retrospective series of 116 cases.".
Guida P; Ragozzino R; Sorrentino B; Casaburi A; D'Amato RD; Federico G; Guida L; Assantino A
Injury; 2016 Jun; 47(6):1222-8. PubMed ID: 27105837
[TBL] [Abstract][Full Text] [Related]
11. Complete twelve month bone remodeling with a bi-phasic injectable bone substitute in benign bone tumors: a prospective pilot study.
Kaczmarczyk J; Sowinski P; Goch M; Katulska K
BMC Musculoskelet Disord; 2015 Nov; 16():369. PubMed ID: 26612576
[TBL] [Abstract][Full Text] [Related]
12. A new β-tricalcium phosphate with uniform triple superporous structure as a filling material after curettage of bone tumor.
Seto S; Muramatsu K; Hashimoto T; Tominaga Y; Taguchi T
Anticancer Res; 2013 Nov; 33(11):5075-81. PubMed ID: 24222152
[TBL] [Abstract][Full Text] [Related]
13. Natural Course of Local Bone Mineralization After Treatment of Benign or Borderline Bone Tumors and Cysts With a Composite Ceramic Bone Graft Substitute.
Horstmann PF; Hettwer WH; Petersen MM
J Clin Densitom; 2018; 21(4):472-479. PubMed ID: 29661685
[TBL] [Abstract][Full Text] [Related]
14. The surgical management of the cavity and bone defects in enchondroma cases: A prospective randomized trial.
Nazarova NZ; Umarova GS; Vaiman M; Asilova SU; Abba M; Foonberg M; Shterenshis M
Surg Oncol; 2021 Jun; 37():101565. PubMed ID: 33848764
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of proximal femoral benign lesions by proximal femoral nail anti-rotation combined with curettage and bone graft through the Watson-Jones approach].
Liu H; Xiong Y; Fang X; Duan H
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2018 Jul; 32(7):893-898. PubMed ID: 30129314
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of juvenile bone cysts by curettage and filling of the cavity with BAS-0 bioactive glass-ceramic material].
Sponer P; Urban K
Acta Chir Orthop Traumatol Cech; 2004; 71(4):214-9. PubMed ID: 15456099
[TBL] [Abstract][Full Text] [Related]
17. Ultraporous β-tricalcium phosphate alone or combined with bone marrow aspirate for benign cavitary lesions: comparison in a prospective randomized clinical trial.
Damron TA; Lisle J; Craig T; Wade M; Silbert W; Cohen H
J Bone Joint Surg Am; 2013 Jan; 95(2):158-66. PubMed ID: 23324964
[TBL] [Abstract][Full Text] [Related]
18. Novel fully interconnected porous hydroxyapatite ceramic in surgical treatment of benign bone tumor.
Tamai N; Myoui A; Kudawara I; Ueda T; Yoshikawa H
J Orthop Sci; 2010 Jul; 15(4):560-8. PubMed ID: 20721726
[TBL] [Abstract][Full Text] [Related]
19. Mid-term results of intralesional extended curettage, cauterization, and polymethylmethacrylate cementation in the treatment of giant cell tumor of bone: A retrospective case series.
Şirin E; Akgülle AH; Topkar OM; Sofulu Ö; Baykan SE; Erol B
Acta Orthop Traumatol Turc; 2020 Sep; 54(5):524-529. PubMed ID: 33155564
[TBL] [Abstract][Full Text] [Related]
20. Treatment of benign bone lesions with an injectable calcium sulfate-based bone graft substitute.
Kelly CM; Wilkins RM
Orthopedics; 2004 Jan; 27(1 Suppl):s131-5. PubMed ID: 14763545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
